{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tivozanib",
    "query": {
      "intervention": "Tivozanib"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 34,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tivozanib&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T10:06:06.674Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00717340",
      "title": "A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combination With Paclitaxel in Subjects With Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "tivozanib (AV-951) + paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2009-02",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00717340"
    },
    {
      "nct_id": "NCT01846871",
      "title": "Tivozanib for Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-06",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-01-08",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01846871"
    },
    {
      "nct_id": "NCT07218692",
      "title": "RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Clear Cell Renal Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Advanced Sarcomatoid Renal Cell Carcinoma",
        "Metastatic Clear Cell Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma",
        "Metastatic Sarcomatoid Renal Cell Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Sturlimogene Erparepvec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2026-08-11",
      "completion_date": "2027-08-11",
      "has_results": false,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Irvine, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07218692"
    },
    {
      "nct_id": "NCT01210846",
      "title": "A Cardiac Safety Study of Tivozanib to Evaluate the Electrocardiogram and Pharmacokinetic-Electrocardiogram Dynamics in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2010-10",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Lafayette, Indiana + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Indiana"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210846"
    },
    {
      "nct_id": "NCT00826878",
      "title": "An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Tivozanib (AV-951)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2009-01",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2012-06-28",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Kansas City, Kansas • New York, New York",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00826878"
    },
    {
      "nct_id": "NCT01807156",
      "title": "Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Cancer"
      ],
      "interventions": [
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2013-03",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01807156"
    },
    {
      "nct_id": "NCT01853644",
      "title": "Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Epithelial Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 110 Years · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2013-06-06",
      "completion_date": "2021-05-11",
      "has_results": true,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Warrenville, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Warrenville",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853644"
    },
    {
      "nct_id": "NCT01363804",
      "title": "A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tivozanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-05",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-06-05",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363804"
    },
    {
      "nct_id": "NCT01030783",
      "title": "A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "tivozanib (AV-951)",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AVEO Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 517,
      "start_date": "2009-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2019-10-28",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Orlando, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01030783"
    },
    {
      "nct_id": "NCT01835223",
      "title": "Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Adult Hepatocellular Carcinoma",
        "Non-Resectable Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tivozanib (1mg)",
          "type": "DRUG"
        },
        {
          "name": "Tivozanib (1.5mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2013-07-11",
      "completion_date": "2019-11-08",
      "has_results": true,
      "last_update_posted_date": "2020-10-28",
      "last_synced_at": "2026-09-03T10:06:06.674Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Cleveland, Ohio",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01835223"
    }
  ]
}